Valink Therapeutics engineers next-generation oncology therapeutics that combine bispecific antibody technology with antibody-drug conjugates to improve efficacy, safety, and precision. Its proprietary discovery platform and V-gate™ approach expand the design space for bsADCs, enabling fine-tuned target control and an improved therapeutic index compared with current ADC technologies. Beyond bsADCs, the company is building a suite of multispecific or multifunctional ADCs and multivalent agonists to address additional therapeutic needs. Valink is advancing two first-in-class oncology programs for solid tumors, including colorectal cancer, which are now moving toward preclinical development. Proceeds from recent financing will fund this pipeline progression and further platform development. The company operates from its headquarters in Cambridge, Massachusetts, with R&D facilities in the United Kingdom.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2025